NL-OMON37620招募中4 期
Can metformin prevent endothelial ischemia and reperfusion injury? The metformin-FMD trial. - The Metformin-FMD trial.
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 26 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age 30-50 years
- •- Written informed consent
排除标准
- •- Hypertension (Psystole > 140mmHg, diastole > 90 mmHg)
- •- Hyperlipidaemia (fasting total cholesterol >5.5 mmol/L or random > 6.5 mmol/L)
- •- Diabetes Mellitus (fasting glucose > 7.0 mmol?L or random glucose > 11.0 mmol/L)
- •- History of any cardiovascular disease
- •- Concomitant chronic use of medication
- •- Renal dysfunction (MDRD < 60 ml/min)
- •- Professional athletes
研究者
相似试验
进行中（未招募）
1 期
Can metformin prevent endothelial ischemia and reperfusion injury?EUCTR2011-005343-27-NLRadboud University Nijmegen Medical Centre25
已完成
4 期
The Metformin-FMD TrialIschemia Reperfusion InjuryEndothelial FunctionNCT01610401Radboud University Medical Center26
已完成
不适用
Metformin improves endothelial function, endothelial progenitor cells and cardiovascular risk factors in type 1 diabetesType 1 diabetes and cardiovascular diseaseNutritional, Metabolic, EndocrineInsulin-dependent diabetes mellitusISRCTN26092132Gateshead Health NHS Foundation Trust (UK)46
招募中
4 期
Investigating the effect of metformin on vascular function and cardiovascular risk factors in children and adolescents with type 1 diabetesType 1 diabetes mellitusIRCT20230930059564N1Shahid Beheshti University of Medical Sciences52
已完成
不适用
The effects of metformin on vascular function and adipocyte AMP-activated protein kinase (AMPK) activation in type 2 diabetesISRCTN51336867Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)20